Hepatitis C Makers Mostly Higher on Gilead/Pharmasset M&A (IDIX, INHX, VRTX)
The deal between Gilead and Phamasset is driving other hepatitis C developers higher this morning. Whether the 90% or so premium is a true read on just how bad this is up to…